Euro Pacific Asset Management 13F: New $203K Stake in BMY
Euro Pacific Asset Management disclosed a new stake in pharmaceutical giant Bristol-Myers Squibb Company in an SEC filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Euro Pacific Asset Management opened a new position of 3,000 shares in Bristol-Myers Squibb Company ($BMY), according to a 13F filing with the SEC dated October 13, 2026. It reported 3,000 shares worth $202,680 at the end of the quarter.
Since the filing, $BMY is up 5.4% to date (from the $56.67 close on Oct 13, 2026).
Find the original: Euro Pacific Asset Management 13F filings on SEC EDGAR
BMY
Bristol-Myers Squibb Company
Key Points
- Euro Pacific Asset Management opened a new position in Bristol-Myers Squibb Company by purchasing 3,000 shares worth about $202,680.
- Major institutional investors adjusted their positions during the quarter, with Blackrock Inc. growing its holdings to 180,384,994 shares.
- Bristol-Myers Squibb Company trades near $60.55, backed by a trailing twelve month revenue of $49.19 billion and an annual dividend yielding 4.16%.
Get $BMY trade alerts by text
We text you when insiders, Congress or big funds trade $BMY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bristol-Myers Squibb Company alert may contain errors. Disclosures
Euro Pacific Asset Management opened a new position in Bristol-Myers Squibb Company (NYSE: BMY), purchasing 3,000 shares valued at roughly $202,680. The investment was revealed in a Form 13F filing submitted to the Securities and Exchange Commission on October 13, 2026. Keep in mind that 13F filings are backward-looking and show holdings as of the end of the reporting quarter, meaning they might not reflect the fund's exact current position today.
Euro Pacific Asset Management vs. the S&P 500
Hypothetical returns from Euro Pacific Asset Management's disclosed trades, not real profit or advice. How we model this.
Inside Euro Pacific Asset Management's Bristol-Myers Squibb Company Trade
The fund established its new stake by acquiring 3,000 shares of the drug maker. Because this is a brand-new holding, there was no prior position or percentage change to report.
Other Institutional Activity in Bristol-Myers Squibb Company
Other large institutional investors made significant adjustments to their Bristol-Myers Squibb Company holdings during the period. Blackrock Inc. grew its holdings by 8,704,215 shares, ending with 180,384,994 shares worth about $10,778,003,391. Vanguard Capital Management LLC added 1,018,856 shares for a total of 133,337,856 shares valued at roughly $7,966,936,896. State Street Corporation boosted its stake by 3,844,031 shares to finish with 102,408,940 shares worth about $6,118,934,165. JPMORGAN CHASE & CO cut back its position by 20,760,371 shares, leaving it with 71,713,442 shares valued at roughly $4,284,878,159. Charles Schwab Investment Management, Inc. lifted its holdings by 6,478,381 shares to reach 67,595,177 shares worth about $4,038,811,825.
Bristol-Myers Squibb Company Stock Up 2.1%
Bristol-Myers Squibb Company recently traded around $60.55 as of October 16, 2026. That price sits below its 50-day moving average while holding above its 200-day average. The stock trades roughly 11.8% below its 52-week high of $68.64 while offering a strong bounce above its 52-week low of $42.52.
Recent Earnings
The drug maker generated trailing-twelve-month revenue of $49,186,000,896 with earnings of $4.54 per share. The company reported a net profit margin of 18.9% and a return on equity of 46.6%. The company is scheduled to report its next earnings results on October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
Analyst view held steady after the report.
-
EPS & revenue
EPS beat estimates by 10.4%. Revenue beat estimates by 4.3%.
-
Profit surprise
EBITDA missed by 13 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
- Analyst signal
-
Earnings quality
Gross margin up 4.7 points. Operating margin down 3.0 points. Positive free cash flow.
Earnings Call Summary
Bristol delivered a solid first quarter with revenue of 11.5 billion dollars, up 1 percent year over year, and earnings per share of 1.58 dollars, beating Wall Street by 10 percent. The growth portfolio grew 9 percent, led by strong performances from Eliquis at 4.1 billion dollars and Breyanzi up 53 percent. Management highlighted progress across pipeline programs including positive data for Pumitamig and upcoming late-year readouts for Factor XI inhibitor Milvexian and Cobenfy in Alzheimer's disease psychosis.
Guidance Bristol reaffirmed its 2026 financial targets and said the company is tracking toward the upper end of guidance. The management team noted strong momentum in the growth portfolio and multiple clinical readouts expected in the second half of the year, including Milvexian in atrial fibrillation and Cobenfy in Alzheimer's psychosis.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Dividend
Bristol-Myers Squibb Company pays an annual dividend yielding 4.16% with a payout ratio of 55.3%.
Insider Buying and Selling at Bristol-Myers Squibb Company
Company insiders have executed several transactions over recent months. Chief Financial Officer David Vincent Elkins disposed of 30,000 shares on April 1, 2026, totaling $1,850,016. Officer Phil M. Holzer sold 500 shares on August 25, 2026, at an average price of $67.50 for a total of $33,750. Officer Cristian Massacesi parted with 6,249 shares on September 9, 2026, at an average price of $64.57, worth $403,498.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock through recent weeks. On September 16, 2026, Piper Sandler reiterated its Overweight rating and raised its price target to $82.00. Leerink Partners downgraded the stock to a Market Perform rating on October 5, 2026, lowering its target to $59.00. Morgan Stanley maintained an Underweight rating on October 7, 2026, with a target of $41.00. Cantor Fitzgerald maintained a Neutral rating on October 8, 2026, lowering its target to $53.00. Wells Fargo maintained an Equal-Weight rating on October 13, 2026, with a target of $60.00. Wall Street analysts currently hold a consensus Buy rating on the stock with a mean price target of $65.63.
About Bristol-Myers Squibb Company
Based in Princeton, New Jersey, Bristol-Myers Squibb Company discovers, develops, and distributes biopharmaceutical products around the world. The healthcare company focuses heavily on treatments for oncology, hematology, immunology, cardiovascular, and neuroscience conditions. Institutional investments like this latest filing highlight how major asset managers position themselves across the large pharmaceutical sector.
Bottom Line
Investors will watch the upcoming earnings release on October 29, 2026, for fresh updates on revenue and profit margins. Future SEC filings will show whether Euro Pacific Asset Management chooses to grow or trim its newly established stake in the months ahead.
Related Filing Alerts
Source: Euro Pacific Asset Management's 13F filing on $BMY (Oct 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Euro Pacific Asset Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts